trending Market Intelligence /marketintelligence/en/news-insights/trending/Oh_ATnrUgxtbKH1a5DBDrw2 content esgSubNav
In This List

ADMA shareholders approve asset acquisition from Biotest

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


ADMA shareholders approve asset acquisition from Biotest

ADMA Biologics Inc. shareholders approved the company's planned acquisition of certain assets from Biotest Pharmaceuticals Corp.

The assets include facilities and certain Biotest employees in Boca Raton, Fla., a U.S. Food and Drug Administration-licensed product portfolio including Nabi-HB and Bivigam, and contract manufacturing and services agreement for a third party's licensed hyperimmune globulin product.

The acquisition is expected to close in June.

Biotest Pharmaceuticals is a wholly owned subsidiary of Biotest AG.